Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Amid talk of “ending HIV,” we must also focus on those with the virus, says Anthony S. Fauci, MD.
These are scary and confusing times. It is understandable to hit the “pause’ button.
Conducted in South Africa, it’s one of three major late-stage trials.
That’s the core message of an essay by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
Major studies have shown that “undetectable equals untransmittable,” meaning that successfully treated HIV cannot transmit via sex.
New forms of treatment and PrEP and, hopefully, an at least partially effective vaccine will be key to fighting the epidemic in the 2020s.
Last year, the federal agency invested nearly $300 million in the search for HIV cure therapies.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.
Expect “Ending the Epidemics realness,” disruptive innovation and Mother Elektra at #2019USCA.
“We’re very happy,” says PAC’s Murray Penner. But he’d like the federal agency to take these additional steps.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!
The CDC holds the patents to Truvada-as-PrEP, but hasn’t asked for a dime in royalties from Gilead. This is costing taxpayers billions. Why?
Broad details emerge, such as targeting the HIV hot spots that, when combined, account for 50 percent of new HIV cases.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.